Travere Therapeutics stock jumped early Tuesday after the FDA approved Filspari for a new kidney disease.
Recent health news highlights significant regulatory and technological advancements in the medical field. South Korea bans syringe stockpiling due to supply concerns amid the Iran conflict, while U.S.
Novo Nordisk and Novartis deepened their ties to AI companies on Tuesday.